-
Higher buprenorphine doses help patients stay in opioid use disorder treatment, new study finds
Patients who are prescribed higher daily doses of the medication buprenorphine for opioid use disorder are significantly more likely to... Read more -
Links between brain regions could predict the efficacy of antidepressants
Major depressive disorder (MDD) is a severe form of depression characterized by a persistent low mood, hopelessness, disruptions in sleep... Read more -
FDA warns Novo Nordisk broke safety reporting rules
Federal regulators have warned the maker of Ozempic and Wegovy that it failed to report possible drug side effects to... Read more -
Kids can take tablets, so why are we still giving liquid medicines?
When six-year-old Seren was prescribed antibiotics, taking them four times a day quickly became a battle. The orange liquid tasted... Read more -
How psychedelics push your brain to dream while awake: New study
A new study in mice suggests psychedelics make the brain more likely to "see" images from memory rather than what's... Read more -
Roflumilast cream has long-term safety, efficacy in young children
For children aged 2 to 5 years with atopic dermatitis (AD), roflumilast cream 0.05% has a favorable long-term safety profile... Read more -
Aligning genomic data and clinical health records identifies potential medications for treating alcohol use disorder
A novel approach has identified drugs in current use that could be repurposed for treating alcohol use disorder (AUD). In... Read more -
What happens when patients stop taking GLP-1 drugs? New study reveals real world insights
As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them... Read more -
Experimental Alzheimer's drug reverses memory loss in mice by reprogramming gene activity
A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering... Read more -
Study finds CDK4/6 plus EGFR blockade kills pancreatic cancer cells without KRAS drugs
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1... Read more -
How vitamin B2 could pave the way to new cancer therapies
The human body cannot produce vitamin B2—also known as riboflavin—itself; it must absorb the important substance through diet. The vitamin... Read more -
Novel compounds open new research avenues for Alzheimer's disease therapeutics
Alzheimer's disease is the most common cause of dementia, and it affects over 7 million people in the United States... Read more -
Berberine as a natural Ozempic? An analysis of a popular myth
In recent years, berberine has increasingly appeared in the public sphere as a "natural way" to improve metabolism. In social... Read more -
FDA provides fast track designation to nipocalimab for systemic lupus erythematosus
Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for... Read more -
Evaluating the effects of hypnotics for insomnia in obstructive sleep apnea
Obstructive sleep apnea (OSA) is a common sleep disorder characterized by oxygen desaturation due to repeated airway collapse during sleep.... Read more
